Merck Revised To $50 On Strong Pipeline

Singulair has witnessed a faster than expected decline in revenues post patent expiry and as such we have lowered our revenue expectations from the drug going forward. This has been offset by increased sales expectations from its legacy animal & consumer health division, which posted moderate growth despite currency challenges.

Source: http://www.forbes.com/sites/greatspeculations/2012/12/13/merck-revised-to-50-on-strong-pipeline/

credit debt elimination credit debt solutions debt advice uk debt advisor